Jacob Lund, PhD

Principal Scientist, Rare Blood Disorders, Rare Disease Research
Novo Nordisk A/S, Måløv, Denmark
Måløv, Hovedstaden, Denmark

Jacob Lund, PhD. Principal Scientist in department of Rare Blood Disorders in Research and Early Development at Novo Nordisk A/S.
Biochemist by training, specialized in hemostasis biochemistry and interested in gene therapy. Early project manager and scientific coordinator. I am experienced and interested in bi-specific antibodies, enzyme kinetics, computational modelling and data visualization among others.

Presentation(s):

• PB0255 - Comparison of FVIII and concizumab in thrombin generation assays under different conditions

  Sunday, June 23, 2024
  13:45 – 14:45 ICT

• OC 21.1 - Novel FVIIIa-mimetic molecule with the potential to be the first oral treatment for severe hemophilia A

  Sunday, June 23, 2024
  14:45 – 15:00 ICT

• OC 50.5 - FVIII In Vitro Bioequivalence of Mim8 Haemostatic Effect by Thrombin Generation Assays

  Tuesday, June 25, 2024
  10:30 – 10:45 ICT